Abstract: A prosthesis or orthosis for a joint, such as an ankle, which includes a first body, a second body, and an articulated joint between the first and second bodies, the articulated joint allowing the rotation of the first and second bodies with respect to one another around a joint rotation axis. It further includes a locking mechanism configured to selectively lock the rotation between the first and second bodies in one direction, when it is in a locked configuration, and a transmission mechanism such that a rotation of the joint rotation axis generates a movement of a lockable part of the locking mechanism. The axis of the movement of the lockable part is shifted relative to the joint rotation axis and the transmission mechanism includes a reducer configured to reduce effort to lock the rotation of the first body with respect to the second body.

Abstract: A polypeptide including the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity of the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. Also, the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.

Abstract: A continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream including an absorption step of the carbon dioxide from a gas stream into an aqueous solution including a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. A system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream including a control unit, an absorption unit and a crystallization unit.

Abstract: Lactam or lactone derivatives of formula Ia: or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is NH or O; X2 is —OH, —O-alkyl, —NH2, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z1 is S, SO, SO2, O, CR3 or NR4; and R1, R2, R3 and R4 each independently are H, alkyl or aryl. Also, the use of lactam or lactone derivatives of formula Ia in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV-2.

Abstract: A structure for an RF device provided with a semiconductor region coated with a heterogeneous dielectric region, the heterogeneous dielectric region including, in at least one first direction parallel to a main plane of the substrate, an alternation of first areas made of a first dielectric material with positive fixed charges and of second dielectric areas made of a second dielectric material with negative fixed charge in order to create an alternation of polarity allowing preventing the formation of a parasitic conduction layer in the semiconductor region.

Abstract: A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.

Abstract: Genetically modified gram-negative bacteria, in particular E. coli, that are oversensitive to lysis. These bacteria are therefore useful to improve the yield of nucleic acid extraction, preferably extra-genomic nucleic acid extraction (e.g. plasmid), and/or the yield of a polypeptide, preferably encoded by an extra-genomic nucleic acid. In practice, the strains of E. coli are engineered with a combination of at least 2 mutated genes altering the envelop integrity. More particularly, at least one mutated gene is ompA and at least one mutated gene is a gene involved in Lpp functionality, such as, e.g., the lpp gene, the ybiS gene, the ycfS gene and the erfK gene. These combinations also include mutations in genes that are homologue to the ompA gene, and/or the lpp gene.

Abstract: An example device includes a processor configured to receive a plurality of voltage values representing respective voltage magnitudes at voltage nodes in a first portion of a power system and determine, for each voltage node, a respective value of first and second voltage-constraint coefficients. The processor is also configured to receive a power value corresponding to a connection point of the first portion of the power system with a second portion of the power system and determine for the connection point, a respective value of first and second power-constraint coefficients. The processor is also configured to cause at least one energy resource connected to the first portion of the power system to modify an output power of the at least one energy resource based on the value of the first and second voltage-constraint coefficients for each voltage node and the value of the first and second power-constraint coefficients.

Abstract: The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver.

Abstract: A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.

Abstract: The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha-2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.

Abstract: The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.

Abstract: The present invention relates generally to the field of plant molecular biology and relates to plants having a modified lipid metabolism and to methods for making such modified plants. In particular, the invention provides modified plants and parts thereof, including seeds, having an increased level of triacylglycerol (TAG), by means of a seed-specific expression in seed tissues during seed filling of a nucleic acid encoding a translocator protein (TSPO) in said modified plants or parts thereof. The invention further relates to methods for modulating lipid metabolism in plants and for producing plants with a modified lipid metabolism. The invention also provides constructs, vectors and host cells useful in the methods of the invention, and further relates to products obtained from the modified plants.

Abstract: A substrate has a front side including an electrical circuit and a rear side including an exposed zone that faces the electrical circuit. In an electrochemical treatment step, an electrical potential is laterally applied at least to the exposed zone of the rear side of the substrate, while the exposed zone is in contact with a chemically reactive substance. The electrical potential causes a lateral flow of electrical current at least in the exposed zone of the substrate. The lateral flow of current and the chemically reactive substance alter the substrate in at least the exposed zone.

Abstract: A device (100) having a proximal end (20) and end a distal end (40) for withdrawal of a liquid sample, fractionation, and separation of one or more fractions comprising: a piston assembly (300) comprising a piston (302) dismountably attached at its proximal end (20) to an actuating rod (350); a container (200) having a body (202) disposed with a cylindrical chamber (204) for slidable movement of the piston (302) therein; wherein the cylindrical chamber (204) is provided at the distal end (40) with a resealable septum (410) for co-operation with a puncture needle assembly (600) for withdrawal of the liquid sample, an at the proximal end (20) with a stop member (206), which stop member (206) limits movement of the piston (300) in a proximal direction, wherein the container body (202) is dimensioned to fit inside a centrifuge rotor, and is configured for breakability into two parts at a temperature of 0 deg C. or lower at a breakable zone (210).

Abstract: A lipid nanocapsule for oral administration including a solid lipid outer shell and a lipophilic liquid inner core having reverse micelles loaded with one or more incretin mimetics. Also, a method for treating and/or preventing a disorder associated with a GLP-1 dysfunction, the method including a step of administering the therapeutically effective amount of the lipid to a subject in need thereof.

Abstract: A vaccine for treating and/or preventing a brain tumor. More particularly, a modified vesicular stomatitis virus glycoprotein (VSV-G) including at least one tumor antigen, or a fragment thereof, for use in preventing and/or treating a brain tumor in an individual in need thereof, when administered before a surgery intended to remove all or part of the tumor, such as, a tumor resection. The inventors have shown that vaccination of individual with a brain tumor with a vaccine including a nucleic acid sequence encoding a modified VSV-G may be combined to a tumor resection in order to ameliorate the prognostic of the individuals.

Abstract: It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells comprising such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.

Abstract: The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.

Abstract: A polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits, and compositions and kits including the polypeptides.